Kiora Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Kiora Pharmaceuticals hat ein Gesamteigenkapital von $34.9M und eine Gesamtverschuldung von $0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $42.4M bzw. $7.5M. Kiora Pharmaceuticals Das EBIT des Unternehmens beträgt $6.2M, so dass der Zinsdeckungsgrad -17.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $31.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	-17.7x
Bargeld	US$31.28m
Eigenkapital	US$34.90m
Gesamtverbindlichkeiten	US$7.54m
Gesamtvermögen	US$42.44m

Jüngste Berichte zur Finanzlage

Recent updates

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

May 21

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: KPRXDie kurzfristigen Aktiva des Unternehmens ($33.5M) übersteigen seine kurzfristigen Passiva ($1.6M).

Langfristige Verbindlichkeiten: KPRXDie kurzfristigen Vermögenswerte des Unternehmens ($33.5M) übersteigen seine langfristigen Verbindlichkeiten ($5.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: KPRX ist schuldenfrei.

Schulden abbauen: KPRX hatte vor 5 Jahren keine Schulden.

Schuldendeckung: KPRX hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: KPRX hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Kiora Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Recent updates

Investor sentiment improves as stock rises 21%

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen